PATENT CLAIM ANALYSIS

Application Number: 15764794
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-11
Patent Classification: ["514", "210210"]

Abstract:
The present disclosure relates to solid dosage forms comprising anti-HCV compounds and methods of using such dosage forms to treat or prevent HCV infection. Direct-acting antiviral agents (DAAs) have a high cure rate, and favorable tolerability in persons infected with hepatitis C virus (HCV). However, shorter courses of therapy can improve adherence, affordability, and increase DAAs accessibility. The addition of an NS3 protease inhibitor to dual NS5A-NS5B (nucleoside) inhibitors enhances antiviral efficacy, and reduces treatment duration to 3 weeks (wks) in individuals with a rapid virologic response (RVR), defined as plasma HCV RNA<500, or <1,000, IU/mL by Day 2 of treatment.

Claim (Index 11):
The method of  claim 10 , further comprising screening HCV positive patients to determine one or both of their HCV base viral load and whether or not they have cirrhosis of the liver before initiating treatment.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 90.0
- Lexical Diversity: 1.46512
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15885630', '13726783', '13935983', '13935987', '13656012']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7120136469132787
- 35 USC 102 Novelty (BERT): 0.5237529728161706
- Combined Prediction Score: 0.6931875795035679
- Mean Citation Score: 264.019582
- Max Citation Score: 286.44485
- Similarity Product: 176.674098516801

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test